drugset
drugset / Trial / NCT05159882

Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

NCT05159882 ↗

Phase 3 Unknown 390 enrolled Newsoara Biopharma Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the effect of THR-1442 compared to Dapagliflozin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Timeline

Start
2021-04-15
Primary completion
2022-09-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexagliflozin Small molecule 20 mg —
Comparator Dapagliflozin Small molecule 10 mg —

Indications

type 2 diabetes mellitus